99mtc-trodat-1 marked freeze-dry article medicine-box and preparation method

Abstract

The invention relates to a freeze-drying product medicine box with a <99m>Tc-Trodat-1 mark and a preparation method thereof, which have a formula as follows: 30 to 150 weight portions of Trodat-1, 30 to 150 weight portions of SnCl2 question mark 2H20, 500 to 5000 weight portions of EDTA, 500 to 5000 weight portions of sodium glucoheptonate and 10000 to 30000 weight portions of cyclodextrin. The invention successfully applies the cyclodextrin in the preparation of Trodat-1 medicine boxes for the first time, thus optimizing the medicine box composition, increasing the stability of the medicine box, reducing adhesion loss of injections and achieving the expected purpose.

Description

technical field [0001] The present invention relates to a 99m Tc-Trodat-1 labeled freeze-dried product kit and preparation method thereof. Background technique [0002] Radiopharmaceuticals refer to radionuclides or their labeled elements, compounds and biological preparations that can be used for clinical diagnosis or treatment. Using it and corresponding nuclear medicine imaging equipment can realize early diagnosis of cardiovascular, brain nervous system diseases and tumors at the molecular level, greatly improving the accuracy and success rate of prevention and treatment of such diseases. Due to the particularity of radiopharmaceuticals (radiation and instability, short half-life, short validity period, etc.), its rapid preparation method and convenient and effective preparation development are important links in its market, and are also the current international research and development of radiopharmaceuticals. Difficulties have become an important content of radiopha...

AI Technical Summary

Problems solved by technology

At present, both at home and abroad are in the stage of preclinical or clinical research, because the Trodat-1 ligand ( 99m The instability of Tc-Trodat-1 (structure as above) makes the research on Trodat-1 kits extremely complicated, and the formulations are also different. Up to now, there are still key quality and technical problems in the preparation of Trodat-1 kits , have not been well resolved, such as: how to prevent the failure of the trace amount of stannous in the kit, prolong the shelf life of the kit, how to safely and effectively reduce the amount of Trodat-1 in the kit to save costs, but at the same time prevent its decomposition products from affecting the brain. For example, how to choose effective stabilizers and excipients to ensure the stability of each component in the kit, prevent their interaction and reduce the radiochemical purity of the labeled drug, and how to reduce the stickiness of the injection due to the high lipid solubility of the marker. Problems such as losses need to be effectively resolved

Images